Literature DB >> 17949282

Combination of Hb Knossos [Cod 27 (G-T)] and IVSII-745 (C-G) in a Turkish patient with beta-thalassemia major.

Ibrahim Keser1, Esra Manguoglu, Ozlem Kayisli, Akif Yesilipek, Guven Luleci.   

Abstract

Beta-thalassemia is the most common disease among hemoglobinopathies in Antalya, Turkey, as well as world-wide. Mutations found in Turkish beta-thalassemia patients constitute a heterogeneous group, consisting mostly of point mutations. Only in very rare cases did deletions or insertions cause affected or carrier phenotypes. Hb Knossos [beta 27 (B9) Ala-Ser] is a rare variant with a normal HbA2 level. In this study, we aimed to investigate the effect of compound heterozygosity for Hb Knossos [Cod 27 (G-T)] and IVSII-745 (C-G). To our knowledge, this is the first report of such a combination related with beta-thalassemia major phenotype in a Turkish family, where reverse dot blot hybridization (RDBH) and DNA sequencing analysis were used. Heterozygous inheritance of the mutation results in mild beta-thalassemia phenotype, whereas homozygous inheritance leads to intermediate beta-thalassemia. As a result, the compound heterozygosity of Hb Knossos with IVSII-745 appears as the cause of the beta-thalassemia major phenotype in our case. The combination of these mutations [Hb Knossos, Cod 27 (G-T), and IVSII-745, C-G] causes the beta-thalassemia major phenotype, and this is important for genetic counseling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17949282     DOI: 10.1089/gte.2006.0521

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  2 in total

1.  Hb Knossos: HBB:c.82G>T Associated with HBB:c.315+1G>A Beta Zero Mutation Causes Thalassemia Intermedia.

Authors:  Hengameh Nasouhipur; Ali Banihashemi; Reza Youssefi Kamangar; Haleh Akhavan-Niaki
Journal:  Indian J Hematol Blood Transfus       Date:  2014-01-31       Impact factor: 0.900

2.  Hb Knossos (HBB: c.82G > T), β-globin CD 5 (-CT) (HBB: c.17_18delCT) and δ-globin CD 59 (-a) (HBD: c.179delA) mutations in a Syrian patient with β-thalassemia intermedia.

Authors:  Faten Moassas; Mohamad Sayah Nweder; Hossam Murad
Journal:  BMC Pediatr       Date:  2019-02-18       Impact factor: 2.125

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.